Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 15/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12686706 | 0.83 | GRM1 (0.53) | CHRM1GRM5NAMPT | |
| SCHEMBL29980676 | 0.83 | GRM1 (0.53) | CHRM1GRM5NAMPT | |
| SCHEMBL13490670 | 0.81 | GRM5 (0.52) | CHRM1GRM5NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL5805903 | 0.81 | NAMPT (0.47) | NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL23210852 | 0.80 | NAMPT (0.46) | GRM5NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2636728 | 0.80 | NAMPT (0.46) | GRM5NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL22920552 | 0.78 | PANK3 (0.62) | NAMPT | |
| SCHEMBL19748764 | 0.78 | PANK3 (0.62) | CHRM1NAMPT | |
| SCHEMBL28878989 | 0.77 | NAMPT (0.43) | NAMPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13490336 | 0.77 | NAMPT (0.43) | NAMPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-09-22 | — | — | US | disclosed |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | Saginiet Biosciences Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3190108-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190308969-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190269694-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2019-09-05 | — | — | US | disclosed |
| US-9809591-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3190108-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170119786-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2017-05-04 | — | — | US | disclosed |
| EP-2683244-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES INC (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160102091-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20140322355-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8871790-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2683244-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | 3-V BIOSCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2012122391-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264737-A1 | Heterocyclic Modulators of Lipid Synthesis | FASN, FADS1, FADS2 | CHRM1 4869/4885GRM5 2344/4885NAMPT 318/4885 |
| US-20140322355-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | CHRM1 4869/4885GRM5 2344/4885NAMPT 318/4885 |
| US-20170119786-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | CHRM1 4804/4885GRM5 2043/4885NAMPT 183/4885 |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | CHRM1 4804/4885GRM5 2043/4885NAMPT 183/4885 |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | CHRM1 4804/4885GRM5 2043/4885NAMPT 183/4885 |
| US-20190308969-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | CHRM1 4829/4885GRM5 2053/4885NAMPT 179/4885 |
| US-20190269694-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | CHRM1 4804/4885GRM5 2043/4885NAMPT 183/4885 |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | CHRM1 4804/4885GRM5 2043/4885NAMPT 183/4885 |
| US-20160102091-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | CHRM1 4869/4885GRM5 2344/4885NAMPT 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.